Prima BioMed Ltd. announced that Professors Eric Pujade-Lauraine, MD, PhD, Christian Marth, MD, PhD, and Ignace Vergote MD, PhD have joined Prima's Clinical Advisory Board to advise on the Company's development of CVac(TM) for the treatment of epithelial ovarian cancer. These researchers and clinicians join Prima's existing clinical advisory board members Jonathon Berek and Bradley Monk in the United States, Walther Kuhn in Germany, and Jeffrey Goh in Australia. Prof. Pujade-Lauraine is founder of the French GINECO Group, which is devoted to clinical research in gynecologic cancer.

He is head of the Women Cancers and Clinical Research Department at Hôpitaux Universitaires Paris Centre, site Hôtel-Dieu, AP-HP. Prof. Marth is Head and Professor of the Department of Obstetrics and Gynecology, Innsbruck Medical University, and president and founder of the Austrian Association for Gynecologic Oncology (AGO), and president elect of the European Network of Gynecological Trials Group (ENGOT). Prof. Ignace Vergote is Head of the Department of Obstetrics and Gynecology and Gynecologic Oncology at the Catholic University of Leuven, Belgium.

Prof. Vergote has been Chairman of the European Organization for Research and Treatment of Cancer (EORTC) Gynecologic Cancer Group from 1997 to 2003, and is currently the chairman of the Protocol committee of that group.